ArticleClinical cancer research : an official journal of the American Association for Cancer Research2015
Emerging Agents and New Mutations in EGFR-Mutant Lung Cancer.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Next-generation sequencing for guiding matched targeted therapies in people with relapsed or metastatic cancer.The Cochrane database of systematic reviews · 2025Pooled it
- Challenges and Advances in the Simulation of Targeted Covalent Inhibitors Using Quantum Computing.The journal of physical chemistry letters · 2025Review
- Optimization of Brigatinib as New Wild-Type Sparing Inhibitors of EGFRACS medicinal chemistry letters · 2022Article
- Osimertinib-induced rapid regression of large metastatic tumor to the pituitary in a patient with lung adenocarcinoma.Surgical neurology international · 2021Article
- Rational Computational Design of Fourth-Generation EGFR Inhibitors to Combat Drug-Resistant Non-Small Cell Lung Cancer.International journal of molecular sciences · 2020Article
- Covalent allosteric modulation: An emerging strategy for GPCRs drug discovery.European journal of medicinal chemistry · 2020Review
- Exploring the Regulation Mechanism of Xihuang Pill,Frontiers in pharmacology · 2020Article
- Acquired EGFR L718V Mutation as the Mechanism for Osimertinib Resistance in a T790M-Negative Non-Small-Cell Lung Cancer Patient.Targeted oncology · 2019Article
- ALK Fusion Partners Impact Response to ALK Inhibition: Differential Effects on Sensitivity, Cellular Phenotypes, and Biochemical Properties.Molecular cancer research : MCR · 2018Article
- Telomerase-Mediated Strategy for Overcoming Non-Small Cell Lung Cancer Targeted Therapy and Chemotherapy Resistance.Neoplasia (New York, N.Y.) · 2018Article
- Present and Future Prospect of Small Molecule & Related Targeted Therapy Against Human Cancer.Vivechan international journal of research · 2018Article
- Renal biopsy-driven molecular target identification in glomerular disease.Pflugers Archiv : European journal of physiology · 2017Review
- Management ofCurrent oncology (Toronto, Ont.) · 2017Review
- Article
- Drug Resistance to EGFR Inhibitors in Lung Cancer.Chemotherapy · 2016Review
Corrections and comments
- Comment on
- Comment on
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Third-generation mutant-specific EGFR tyrosine kinase inhibitors are showing robust clinical activity, particularly in lung cancers harboring the EGFR(T790M) mutation, yet acquired resistance to these agents emerges. Additional mutations in EGFR can confer resistance that, depending on their genomic context, could determine new drug sensitivities of the cancer cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.